Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders

References

• Goldman L. 1963; The response of skin cancer to topical therapy with 5-fluorouracil. Cancer Chemother Rep. 28:49–52.
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 2003; 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–8.
   PubMed Web of Science ®Google Scholar
• Eaglstein WH, Weinstein GD, Frost P. 1970; Fluorouracil: Mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 101:132–9.
   PubMedGoogle Scholar
• Fluoroplex [package insert]. Irvine, CA: Allergan, Inc.; 2004.
   Google Scholar
• Efudex [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals North America; 2005.
   Google Scholar
• Carac [package insert]. Bridgewater, NJ: Dermik Laboratories; 2006.
   Google Scholar
• Klein E, Helm F, Milgrom H, Stoll HL Jr, Traenkle HL. 1962; Tumors of the skin. II. Keratoacanthoma; local effect of 5-fluorouracil. Skin (Los Angeles). 1:153–6.
   PubMedGoogle Scholar
• Jansen GT, Dillaha CJ, Honeycutt WM. 1967; Bowenoid conditions of the skin: Treatment with topical 5-fluorouracil. South Med J. 60:185–8.
   PubMed Web of Science ®Google Scholar
• Allison JR Jr. 1967; The topical use of fluorouracil in the treatment of cancers and precancers. J S C Med Assoc. 63:239–41.
   Google Scholar
• Moy RL. 2000; Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 42:(1 Pt 2)S8–S10.
   Google Scholar
• Salasche SJ. 2000; Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 42:(1 Pt 2)S4–S7.
   Google Scholar
• Fuchs A, Marmur E. 2007; The kinetics of skin cancer: Progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 33:1099–101.
   PubMed Web of Science ®Google Scholar
• Oppel T, Korting HC. 2004; Actinic keratosis: The key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 17:67–76.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. 2003; Actinic keratosis: Epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 149:(suppl 66)31–3.
   Google Scholar
• American Academy of Dermatology, American Cancer Society, Skin Cancer Foundation. 1999; Patients urged to seek treatment for actinic keratoses, recommends the American Academy of Dermatology, the American Cancer Society, and the Skin Cancer Foundation. Cutis. 63:348.
   Google Scholar
• De Berker D, McGregor JM, Hughes BR, for the British Association of Dermatologists Therapy Guidelines and Audit Subcommitte. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222–30.
   PubMed Web of Science ®Google Scholar
• Jorizzo JL. 2004; Current and novel treatment options for actinic keratosis. J Cutan Med Surg. 8:(suppl 3)13–21.
   Google Scholar
• Gupta AK, Davey V, Mcphail H. 2005; Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 9:209–14.
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. 2007; A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 157:(suppl 2)34–40.
   PubMed Web of Science ®Google Scholar
• McIntyre WJ, Downs MR, Bedwell SA. 2007; Treatment options for actinic keratoses. Am Fam Physician. 76:667–71.
   PubMed Web of Science ®Google Scholar
• Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. 2003; Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod. Cutis. 71:365–70.
   PubMed Web of Science ®Google Scholar
• Tanghetti E, Werschler WP. 2007; Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 6:144–7.
   PubMedGoogle Scholar
• Simmonds WL. 1973; Double-blind investigation comparing a 1%-vs-5% 5-fluorouracil topical cream in patients with multiple actinic keratoses. Cutis. 12:615–17.
   Google Scholar
• Loven K, Stein L, Furst K, Levy S. 2002; Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 24:990–1000.
   PubMed Web of Science ®Google Scholar
• Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, 2002; Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 70:(2 suppl)22–9.
   PubMedGoogle Scholar
• Gupta AK. 2002; The management of actinic keratoses in the United States with topical fluorouracil: A pharmacoeconomic evaluation. Cutis. 70:(2 suppl)30–6.
   PubMedGoogle Scholar
• Jeffes EW, Mccullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. 2001; Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 45:96–104.
   PubMed Web of Science ®Google Scholar
• Jorizzo J, Weiss J, Furst K, Vandepol C, Levy SF. 2004; Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 140:813–16.
   PubMedGoogle Scholar
• Epstein E. 1977; Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol. 113:906–8.
   PubMedGoogle Scholar
• Gross K, Kircik L, Kricorian G. 2007; 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 33:433–40.
   PubMed Web of Science ®Google Scholar
• Mohs FE, Jones DL, Bloom RF. 1978; Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 114:1021–2.
   PubMedGoogle Scholar
• Romagosa R, Saap L, Givens M, Salvarrey A, He JL, Hsia SL, 2000; A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg. 26:338–40.
   PubMed Web of Science ®Google Scholar
• Ondo AL, Mings SM, Pestak RM, Shanler SD. 2006; Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 55:1092–4.
   PubMed Web of Science ®Google Scholar
• Sturm HM. 1979; Bowen's disease and 5-fluorouracil. J Am Acad Dermatol. 1:513–22.
   PubMedGoogle Scholar
• Thiele JJ, Ziemer M, Fuchs S, Elsner P. 2004; Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg. 30:(12 Pt 2)1556–60.
   Google Scholar
• Gray RJ, Meland NB. 2000; Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg. 44:82–5.
   PubMed Web of Science ®Google Scholar
• Singal A, Mohanty S, Bhattacharya SN, Baruah MC, Singh N. 1997; Unusual multiple keratoacanthoma in a child successfully treated with 5-fluorouracil. J Dermatol. 24:546–8.
   Google Scholar
• Ebner H, Mischer P. 1975; [The local treatment of the keratoacanthoma with 5-fluorouracil.]. Hautarzt. 26:585–8.
   Google Scholar
• Grupper C. 1970; Treatment of keratoacanthomas by local applications of the 5-fluorouracil (5-FU) ointment. Dermatologica. 140:(suppl I)127–32.
   Google Scholar
• Goette DK, Odom RB, Arrott JW, Diakon NC, Horn RT Jr. 1982; Treatment of keratoacanthoma with topical application of fluorouracil. Arch Dermatol. 118:309–11.
   Google Scholar
• Senff H, Reinel D, Matthies C, Witts D. 1988; Topical 5-fluorouracil solution in the treatment of warts – Clinical experience and percutaneous absorption. Br J Dermatol. 118:409–14.
   Google Scholar
• Salk RS, Grogan KA, Chang TJ. 2006; Topical 5% 5-fluorouracil cream in the treatment of plantar warts: A prospective, randomized, and controlled clinical study. J Drugs Dermatol. 5:418–24.
   PubMedGoogle Scholar
• Hursthouse MW. 1975; A controlled trial on the use of topical 5-fluorouracil on viral warts. Br J Dermatol. 92:93–6.
   PubMedGoogle Scholar
• Schmidt H, Jacobsen FK. 1981; [Double-blind randomized clinical study on treatment of warts with a fluorouracil-containing topical preparation (author's transl).] Z. Hautkr. 56:41–3.
   Google Scholar
• Gibbs S, Harvey I. 2006; Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 3:CD001781–.
   Google Scholar
• de Berker D. 2000; Management of nail psoriasis. Clin Exp Dermatol. 25:357–62.
   PubMed Web of Science ®Google Scholar
• Fredriksson T. 1974; Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 110:735–6.
   PubMedGoogle Scholar
• de Jong EM, Menke HE, van Praag MC, van de Kerkhof PC. 1999; Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatology. 199:313–18.
   PubMed Web of Science ®Google Scholar
• Sethi S, Mahajan BB, Gupta RR, Ohri A. 2007; Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo. Int J Dermatol. 46:875–9.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Hamada T. 1983; Topically administered fluorouracil in vitiligo. Arch Dermatol. 119:722–7.
   PubMed Web of Science ®Google Scholar